摘要
T辅助细胞(Th)是适应性免疫系统,提供了一个有效的和特异性宿主的保护手段。Th17细胞是Th细胞亚群,由炎性细胞因子白细胞介素(IL)- 17A(IL-17A)和IL-17F,绑定到受体IL-17RA和IL-17RC亚基组成的复合体。Th17细胞抵抗外细胞和真菌感染,但有伴随的自身免疫性疾病。在许多自身免疫性疾病,异常免疫反应涉及到免疫系统中的几个部分,包括抗体、T细胞和B细胞。有针对性的生物疗法是有吸引力的,因为它们可以防止患者的不必要的副作用。这是不断完善的证据:Th17细胞针对在肾小球免疫性疾病中,血管性或化学性损伤对肾小管的损伤,无论是通过一个特定的攻击肾小球基底膜或全身炎症性疾病的一部分,对肾脏是非常重要的。靶向治疗IL-17A、IL-12p40和IL-17RA的临床试验正在研究或正在使用于临床实践中对其他治疗IL-17介导的疾病,如银屑病。本文探讨IL-17A和Th17细胞可能在免疫性肾脏疾病致病的目前证据,包括抗肾小球基底膜病、抗中性粒细胞胞浆抗体相关性血管炎,狼疮性肾炎,以及急性肾损伤。它将讨论生物制剂对IL-17A、IL-12p40和IL-17RA在治疗这些疾病的部位。
关键词: 急性肾损伤,抗肾小球基底膜病、抗中性粒细胞胞浆抗体相关性血管炎,白细胞介素17,白细胞介素12p40,系统性红斑狼疮,Th17细胞。
Current Medicinal Chemistry
Title:Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Volume: 22 Issue: 38
Author(s): Joanna R. Ghali, Stephen R. Holdsworth and A. Richard Kitching
Affiliation:
关键词: 急性肾损伤,抗肾小球基底膜病、抗中性粒细胞胞浆抗体相关性血管炎,白细胞介素17,白细胞介素12p40,系统性红斑狼疮,Th17细胞。
摘要: T helper (Th) cells belong to the adaptive immune system and provide an effective and antigen-specific means of host protection. Th17 cells are a subset of Th cells, characterized by the production of the inflammatory cytokines interleukin (IL)-17A (IL-17A) and IL-17F, which bind to a receptor complex comprised of IL-17RA and IL-17RC subunits. Th17 cells combat extracellular and fungal infections, but have been implicated in autoimmune diseases. In many autoimmune conditions, the dysregulated immune response involves several parts of the immune system, including autoantibodies, B and T cells. Targeted biological therapies are appealing, as they may prevent unwanted side effects in patients. There is evolving evidence that Th17 cells are important in the kidney, mediating injury in response to vascular or chemical insults to the renal tubules, and in autoimmune diseases of the glomerulus, either through a specific attack on the glomerular basement membrane or as part of a generalized systemic inflammatory disease. Therapies targeting IL-17A, IL-12p40 and IL-17RA are being explored in clinical trials or are being utilized in clinical practice for the treatment of other IL-17 mediated diseases, such as psoriasis. This review explores the current evidence that IL-17A and Th17 cells may be pathogenic in immune kidney disease, including anti-glomerular basement membrane disease, antineutrophil cytoplasmic antibody associated vasculitis and lupus nephritis, as well as in acute kidney injury. It will discuss the place that biological agents against IL-17A, IL-12p40 and IL-17RA may have in the treatment of these conditions.
Export Options
About this article
Cite this article as:
Joanna R. Ghali, Stephen R. Holdsworth and A. Richard Kitching , Targeting IL-17 and IL-23 in Immune Mediated Renal Disease, Current Medicinal Chemistry 2015; 22 (38) . https://dx.doi.org/10.2174/0929867322666151030163022
DOI https://dx.doi.org/10.2174/0929867322666151030163022 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Editorial: MRI of the Small Bowel
Current Medical Imaging Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned
Reviews on Recent Clinical Trials Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention
Current Drug Targets - Inflammation & Allergy The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared
Drug Metabolism Letters Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Role of DAP12 in Innate and Adaptive Immune Responses
Current Pharmaceutical Design The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression
Current Drug Targets